Get started
CATALYST PHARMACEUTICALS INCCATALYST PHARMACEUTICALS INCCATALYST PHARMACEUTICALS INC

CATALYST PHARMACEUTICALS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CN2 chart


Full chart

CN2 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.45 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
17.95
Basic EPS (TTM)
1.11 EUR
Net income (FY)
‪64.70 M‬ EUR
Revenue (FY)
‪360.78 M‬ EUR
Shares float
‪105.83 M‬
Beta (1Y)
1.25

Employees


Employees (FY)
167
Change (1Y)
+85 +103.66%
Revenue / Employee (1Y)
‪2.38 M‬ EUR
Net income / Employee (1Y)
‪427.60 K‬ EUR

About Catalyst Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Richard John Daly
Headquarters
Coral Gables
Website
catalystpharma.com
Founded
2002
FIGI
BBG000H5N1W6
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CN2 news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CN2 is 20.59 EUR — it has increased by 2.49% in the past 24 hours. Watch CATALYST PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange CATALYST PHARMACEUTICALS INC stocks are traded under the ticker CN2.
CN2 stock has risen by 2.08% compared to the previous week, the month change is a 5.54% rise, over the last year CATALYST PHARMACEUTICALS INC has showed a 61.81% increase.
We've gathered analysts' opinions on CATALYST PHARMACEUTICALS INC future price: according to them, CN2 price has a max estimate of 36.06 EUR and a min estimate of 26.57 EUR. Watch CN2 chart and read a more detailed CATALYST PHARMACEUTICALS INC stock forecast: see what analysts think of CATALYST PHARMACEUTICALS INC and suggest that you do with its stocks.
CN2 reached its all-time high on Nov 7, 2024 with the price of 23.32 EUR, and its all-time low was 3.58 EUR and was reached on Apr 16, 2021. View more price dynamics on CN2 chart.
See other stocks reaching their highest and lowest prices.
CN2 stock is 4.73% volatile and has beta coefficient of 1.25. Track CATALYST PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is CATALYST PHARMACEUTICALS INC there?
Today CATALYST PHARMACEUTICALS INC has the market capitalization of ‪2.46 B‬, it has increased by 3.17% over the last week.
Yes, you can track CATALYST PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
CATALYST PHARMACEUTICALS INC is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
CN2 earnings for the last quarter are 0.31 EUR per share, whereas the estimation was 0.27 EUR resulting in a 15.13% surprise. The estimated earnings for the next quarter are 0.33 EUR per share. See more details about CATALYST PHARMACEUTICALS INC earnings.
CATALYST PHARMACEUTICALS INC revenue for the last quarter amounts to ‪113.55 M‬ EUR, despite the estimated figure of ‪110.84 M‬ EUR. In the next quarter, revenue is expected to reach ‪128.70 M‬ EUR.
CN2 net income for the last quarter is ‪39.41 M‬ EUR, while the quarter before that showed ‪38.09 M‬ EUR of net income which accounts for 3.49% change. Track more CATALYST PHARMACEUTICALS INC financial stats to get the full picture.
No, CN2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has 167.00 employees. See our rating of the largest employees — is CATALYST PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CATALYST PHARMACEUTICALS INC EBITDA is ‪190.08 M‬ EUR, and current EBITDA margin is 30.12%. See more stats in CATALYST PHARMACEUTICALS INC financial statements.
Like other stocks, CN2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CATALYST PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CATALYST PHARMACEUTICALS INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CATALYST PHARMACEUTICALS INC stock shows the strong buy signal. See more of CATALYST PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.